Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines: Effect on sulfatase activity in comparison to medroxyprogesterone acetate

Journal of Steroid Biochemistry and Molecular Biology

Volumn 84, Issue 2-3, 2003, Pages 193-198

  Pasqualini, Jorge R ^a   Caubel, Patrick ^b   Friedman, Andrew J ^c   Philippe, Jean Claude ^a   Chetrite, Gérard Samuel ^a  

^a Institut de Puericulture   (France)

^b JOHNSON AND JOHNSON   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Estradiol; Medroxyprogesterone acetate; Norelgestromin

Indexed keywords

DRUG METABOLITE; ESTRONE SULFATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORELGESTROMIN; NORGESTIMATE; SULFATASE; UNCLASSIFIED DRUG;

BREAST CARCINOMA; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; STATISTICAL SIGNIFICANCE;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0242585039     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00058-X     Document Type: Conference Paper

References (25)

1. A. Segaloff, Hormones and mammary carcinogenesis, in: W.L. McGuire (Ed.), Breast Cancer 2 - Advances in Research and Treatment: Experimental Biology, Plenum Press, New York, 1978, pp. 1-22.
2. M.A. Kirschner, The role of hormones in the development of human breast cancer, in: W.L. McGuire (Ed.), Breast-Cancer 3 - Advances in Research and Treatment: Current Topics, Plenum Press, New York, 1979, pp. 199-226.
3. Henderson B.E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 48:1988;246-253.
4. Vermeulen A., Deslypere J.P., Paridaens R., Leclercq G., Roy F., Heuson J.C. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. 22:1986;515-525.
5. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.-C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer. J. Clin. Endocr. Metab. 81:1996;1460-1464.
6. Pasqualini J.R., Cortes-Prieto J., Chetrite G., Talbi M., Ruiz A. Concentrations of estrone, estradiol, and their sulfates and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int. J. Cancer. 70:1997;639-643.
7. Chetrite G., Cortes-Prieto J., Philippe J.C., Wright F., Pasqualini J.R. Comparison of estrogen copncentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Molec. Biol. 72:2000;23-27.
8. van Landeghem A.A.J., Poortman J., Nabuurs M., Thijssen J.H.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45:1985;2900-2906.
9. Abul-Hajj Y.J., Iverson R., Kiang D.T. Aromatization of androgens by human breast cancer. Steroids. 33:1978;205-222.
10. Perel E., Wilkins D., Killinger D.W. The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J. Steroid Biochem. 13:1980;89-94.
11. Dao T.L., Hayes C., Libby P.R. Steroid sulfatase activities in human breast tumors. Proc. Soc. Expl. Biol. Med. 146:1974;381-384.
12. Vignon F., Terqui M., Westley B., Derocq D., Rochefort H. Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology. 106:1980;1079-1086.
13. Pasqualini J.R., Gelly C., Lecerf F. Estrogen sulfates: biological and ultrastructural responses and metabolism in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 8:1986;233-240.
14. J.R. MacIndoe, with the technical assistance of G. Woods, L. Jeffries, M. Hinkhouse, The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells, Endocrinology 123 (1988) 1281-1287.
15. Pasqualini J.R., Gelly C., Nguyen B.-L., Vella C. Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. 34:1989;155-163.
16. Abul-Hajj Y.J., Iverson R., Kiang D.T. Estradiol 17β-dehydrogenase and estradiol binding in human mammary tumors. Steroids. 33:1979;477-484.
17. 3H -oestradiol by normal breast and breast tumour tissues in post-menopausal women Int. J. Cancer. 38:1986;193-196.
18. Santner S.J., Feil P.D., Santen R.J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocr. Metab. 59:1984;29-33.
19. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62:1956;315-323.
20. Phillips A. The selectivity of a new progestin. Acta Obstet. Gynecol. Scand. Suppl. 152:1990;21-24.
21. McGuire J.L., Phillips A., Hahn D.W., Tolman E.L., Flor S., Kafrissen M.E. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Am. J. Obstet. Gynecol. 163:1990;2127-2131.
22. Madden S., Back D.J. Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro. J. Steroid Biochem. Molec. Biol. 38:1991;497-503.
23. Abrams L.S., Skee D.M., Natarajan J., Wong F.A., Anderson G.D. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br. J. Clin. Pharmacol. 53:2002;141-146.
24. Nishimura R., Nagao K., Matsuda M., Baba K., Matsuoka Y., Yamashita H., Fukuda M., Higuchi A., Saiki T. Benefits of medroxyprogesterone acetate (MPA) in advanced or recurrent breast cancer with higher serum concentration. Breast Cancer. 2:1995;133-141.
25. Koyama H. Adjuvant therapy with high-dose medroxyprogesterone acetate for operable breast cancer. Breast Cancer. 6:1999;99-107.